Genel
Daraxonrasib vs. pancreatic cancer: Experimental pill helped people live longer
New research shows a novel pill is helping people with advanced pancreatic cancer live longer. It's not a cure, as the drug's effects eventually waned....
Read More
Genel
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
...
Read More
Genel
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
...
Read More
Genel
Game 7: Spurs at Thunder to decide Western Conference crown
For the 160th time in NBA history and fifth time this season alone, a Game 7 awaits on Saturday night....
Read More
Genel
Women's FA Cup final LIVE: Brighton & Hove Albion vs Manchester City - score, radio commentary, text updates & match stats
Listen to BBC Radio 5 Live commentary and follow live text coverage as Brighton & Hove Albion take on Manchester City in the Women's FA Cup final....
Read More
Genel
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
...
Read More
Genel
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
...
Read More
Genel
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
...
Read More
Genel
Festival honoring Lithuania’s iconic cold beet soup brings thousands to Vilnius
A festival honoring Lithuania’s iconic cold beet soup has brought tens of thousands of visitors to its capital city that was fully decked out in pink....
Read More
Genel
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
...
Read More1
2
3
4
5
6
7
8
9
10
